Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation

被引:79
作者
Zu, Yuangang [1 ]
Sun, Wei [1 ]
Zhao, Xiuhua [1 ]
Wang, Weiguo [1 ]
Li, Yong [1 ]
Ge, Yunlong [1 ]
Liu, Ying [1 ]
Wang, Kunlun [1 ]
机构
[1] Northeast Forestry Univ, Minist Educ, Key Lab Forest Plant Ecol, Harbin 150040, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Amphotericin B; Nanoparticles; LAP; Oral; Preparation; Characterization; LIPID-BASED FORMULATIONS; IN-VITRO; SOLUBLE DRUGS; DELIVERY; NANOSUSPENSIONS; DISSOLUTION; CALCIUM;
D O I
10.1016/j.ejps.2013.12.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We prepared amphotericin B (AmB) nanoparticles through liquid antisolvent precipitation (LAP) and by freeze-drying to improve the solubility of AmB for oral administration. The LAP was optimized through a single-factor experiment. We determined the effects of surfactants and their concentration, the stirring time, the precipitation temperature, the stirring intensity, the drug concentration and the volume ratio of antisolvent to solvent on the mean particle size (MPS) of the AmB nanoparticles. Increased stirring intensity and precipitation time favored AmB nanoparticles with smaller MPS, but precipitation times exceeding 30 min did not further reduce the MPS. Increased Tween-80 concentration and the drug concentration decreased the MPS of the AmB nanoparticles. Increased precipitation temperature and antisolvent to solvent volume ratio initially decreased the MPS of the AmB nanoparticles, which increased thereafter. Optimum conditions produced AmB nanoparticles with an MPS of 135.1 nm. The AmB nanoparticles were characterized through scanning electron microscopy (SEM), mass spectrometry (MS), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermal gravimetric analysis (TG), solvent residue, drug purity test, and dissolution testing. The analyses indicated that the chemical structure of AmB remained unchanged in the nanoparticles, but the structure was changed from crystalline to amorphous. The residual DMSO in the nanoparticles was 0.24% less than the standard set by the International Conference on Harmonization limit for class III solvents. The AmB nanoparticles exhibited 2.1 times faster dissolution rates and 13 times equilibrium solubility compared with the raw drug. The detection results indicate that the AmB nanoparticles potentially improved the oral absorption of AmB. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:109 / 117
页数:9
相关论文
共 30 条
[1]   Lipid formulations of amphotericin B: where are we today? [J].
Antoniadou, A ;
Dupont, B .
JOURNAL DE MYCOLOGIE MEDICALE, 2005, 15 (04) :230-238
[2]   Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation [J].
Chiou, Herbert ;
Li, Li ;
Hu, Tingting ;
Chan, Hak-Kim ;
Chen, Jian-Feng ;
Yun, Jimmy .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 331 (01) :93-98
[3]   Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives [J].
Cho, Eunbi ;
Cho, Wonkyung ;
Cha, Kwang-Ho ;
Park, Junsung ;
Kim, Min-Soo ;
Kim, Jeong-Soo ;
Park, Hee Jun ;
Hwang, Sung-Joo .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 396 (1-2) :91-98
[4]   Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B [J].
Das, Swarnali ;
Suresh, Preeti K. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (02) :242-247
[5]   Determination of free and liposomal Amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques [J].
Deshpande, Niranjan M. ;
Gangrade, Manish G. ;
Kekare, Maharudra B. ;
Vaidya, Vikas V. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2010, 878 (3-4) :315-326
[6]   A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs [J].
Dong, Yuancai ;
Ng, Wai Kiong ;
Hu, Jun ;
Shen, Shoucang ;
Tan, Reginald B. H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 386 (1-2) :256-261
[7]   Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(ε-caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B [J].
Falamarzian, Arash ;
Lavasanifar, Afsaneh .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2010, 81 (01) :313-320
[8]   Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations [J].
Fukui, H ;
Koike, T ;
Nakagawa, T ;
Saheki, A ;
Sonoke, S ;
Tomii, Y ;
Seki, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 267 (1-2) :101-112
[9]   Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying [J].
Hu, Jun ;
Ng, Wai Kiong ;
Dong, Yuancai ;
Shen, Shoucang ;
Tan, Reginald B. H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 404 (1-2) :198-204
[10]   Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model [J].
Ibrahim, Fady ;
Gershkovich, Pavel ;
Sivak, Olena ;
Wasan, Ellen K. ;
Wasan, Kishor M. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 46 (05) :323-328